ArriVent’s firmonertinib fails primary Phase 3 FURVENT endpoint in EGFR exon 20 NSCLC

This is a new, material clinical-study outcome: ArriVent reported that firmonertinib failed the primary progression-free-survival endpoint in the Phase 3 FURVENT trial. The result can reduce approval, commercialization, and asset-value expectations for ArriVent, while modestly reducing competitive pressure on Johnson & Johnson’s amivantamab-based treatment. Importance is high because this is a pivotal trial readout, although the impact is primarily company- and indication-specific. Surprise is moderate because no explicit market consensus or expected result is provided. The October 6, 2026 date is explicit, but the actual announcement time is not; the timestamp is therefore normalized to the start of that UTC date rather than using the source publication time. The source also mentions a share-price halt, which is excluded because price or trading activity is not itself a development. Only AVBP and JNJ are approved as stakeholders; other proposed read-throughs are too indirect or speculative, and no FURVENT-specific relationship is established for them.